Regional Brain Glucose Metabolism and Its Prognostic Value in Pretreatment Extranodal Natural Killer/T-Cell Lymphoma Patients

References

• Lin M, Huang G, Sun X, Ni J. The preliminary study of brain metabolic changes in lung cancer patients of different stages. Chin J Clin Med. 2009;16(4):516–518.
   Google Scholar
• Tashiro M, Kubota K, Itoh M, et al. Regional cerebral glucose metabolism of patients with malignant diseases in different clinical phases. Med Sci Monit. 2001;7(2):226–232.
   PubMed Web of Science ®Google Scholar
• Ni J, Lin M, Liu J, Huang G. Regional brain metabolism changes in the body malignant tumor patients without brain metastasis. Chin J Med Imaging Technol. 2010;26(11):2175–2178.
   Google Scholar
• Machado AMC, Fagundes TC, Mafra A, Silva RG, Castro ACG, Mamede M. Effects on 18F-FDG PET/CT brain glucose metabolism in rectal cancer patients undergoing neoadjuvant chemotherapy. Clin Nucl Med. 2017;42:e484–e490. doi:10.1097/RLU.0000000000001862
   PubMed Web of Science ®Google Scholar
• Nonokuma M, Kuwabara Y, Takano K, Tamura K, Ishitsuka K, Yoshimitsu K. Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis. Ann Nucl Med. 2014;28(10):950–960. doi:10.1007/s12149-014-0890-1
   PubMed Web of Science ®Google Scholar
• Hanaoka K, Hosono M, Shimono T, et al. Decreased brain FDG uptake in patients with extensive non-Hodgkin’s lymphoma lesions. Ann Nucl Med. 2010;24(10):707–711. doi:10.1007/s12149-010-0415-5
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood. 2004;103(1):216–221. doi:10.1182/blood-2003-05-1401
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–618. doi:10.1200/JCO.2005.04.1384
   PubMed Web of Science ®Google Scholar
• Yao N, Hou Q, Zhang S, et al. Prognostic nutritional index, another prognostic factor for extranodal natural killer/T cell lymphoma, nasal type. Front Oncol. 2020;10:877. doi:10.3389/fonc.2020.00877
   PubMed Web of Science ®Google Scholar
• Wang H, Shen G, Jiang C, Li L, Cui F, Tian R. Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: a meta-analysis. PLoS One. 2018;13(3):e0194435. doi:10.1371/journal.pone.0194435
   PubMed Web of Science ®Google Scholar
• Guo R, Xu P, Xu H, Miao Y, Li B. The predictive value of pre-treatment 18 F-FDG PET/CT on treatment outcome in early-stage extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2020;61:2659–2664. doi:10.1080/10428194.2020.1783446
   PubMed Web of Science ®Google Scholar
• Qin C, Yang S, Sun X, Xia X, Li C, Lan X. 18F-FDG PET/CT for prognostic stratification of patients with extranodal natural killer/T-cell lymphoma. Clin Nucl Med. 2019;44(3):201–208. doi:10.1097/RLU.0000000000002440
   PubMed Web of Science ®Google Scholar
• Huang JJ, Zhu YJ, Xia Y, et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol. 2012;29(3):2183–2190. doi:10.1007/s12032-011-0030-x
   PubMed Web of Science ®Google Scholar
• Lister T. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–1636. doi:10.1200/JCO.1989.7.11.1630
   PubMed Web of Science ®Google Scholar
• Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–340. doi:10.1016/S1474-4422(08)70060-7
   PubMed Web of Science ®Google Scholar
• Mackay M, Tang CC, Volpe BT, et al. Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Sci Med. 2015;2(1):e000074. doi:10.1136/lupus-2014-000074
   PubMedGoogle Scholar
• Clapp AJ, Hunt CH, Johnson GB, Peller PJ. Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes. Clin Nucl Med. 2013;38(4):241–247. doi:10.1097/RLU.0b013e3182815f28
   PubMed Web of Science ®Google Scholar
• Chiaravalloti A, Pagani M, Cantonetti M, et al. Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: an (18)F-FDG PET/CT study. Oncol Lett. 2015;9(2):685–690. doi:10.3892/ol.2014.2765
   PubMed Web of Science ®Google Scholar
• Zhang W, Ning N, Li X, et al. Changes of brain glucose metabolism in the pretreatment patients with non-small cell lung cancer: a retrospective PET/CT study. PLoS One. 2016;11(8):e0161325. doi:10.1371/journal.pone.0161325
   PubMed Web of Science ®Google Scholar
• D’Agata F, Costa T, Caroppo P, et al. Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network. EJNMMI Res. 2013;3(1):22. doi:10.1186/2191-219X-3-22
   PubMedGoogle Scholar
• Wedding U, Koch A, Rohrig B, et al. Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy. Acta Oncol. 2008;47(1):56–62. doi:10.1080/02841860701460541
   PubMed Web of Science ®Google Scholar
• Mehnert A, Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psycho-oncol. 2007;16(3):181–188. doi:10.1002/pon.1057
   PubMed Web of Science ®Google Scholar
• Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004;101(3):466–475. doi:10.1002/cncr.20393
   PubMed Web of Science ®Google Scholar
• Hsieh TC, Wu YC, Yen KY, Chen SW, Kao CH. Early changes in brain FDG metabolism during anticancer therapy in patients with pharyngeal cancer. J Neuroimaging. 2014;24(3):266–272. doi:10.1111/jon.12006
   PubMed Web of Science ®Google Scholar
• Chiaravalloti A, Pagani M, Di Pietro B, et al. Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin’s lymphoma? Nucl Med Commun. 2013;34(1):57–63. doi:10.1097/MNM.0b013e32835aa7de
   PubMed Web of Science ®Google Scholar
• Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev. 2009;33(5):699–771.
   PubMed Web of Science ®Google Scholar
• Niida A, Niida R, Matsuda H, Inada T, Motomura M, Uechi A. Identification of atrophy of the subgenual anterior cingulate cortex, in particular the subcallosal area, as an effective auxiliary means of diagnosis for major depressive disorder. Int J Gen Med. 2012;5:667–674. doi:10.2147/IJGM.S34093
   PubMedGoogle Scholar
• Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390–398. doi:10.2967/jnumed.107.045385
   PubMed Web of Science ®Google Scholar
• Temoshok LR. Psychological response and survival in breast cancer. Lancet. 2000;355(9201):404–405. doi:10.1016/S0140-6736(05)74024-1
   PubMedGoogle Scholar
• Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40(9):1321–1329. doi:10.1007/s00259-013-2443-6
   PubMed Web of Science ®Google Scholar